{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:53:49Z","timestamp":1762458829510},"reference-count":41,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R\u2010CHOP) is one of the most frequently applied initial treatments for indolent B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL); however, information on its long\u2010term outcome is limited. Untreated patients in the concurrent arm (Arm C) received six R (375\u2003mg\/m<jats:sup>2<\/jats:sup>) treatments, 2\u2003days prior to each cycle of CHOP, and patients in the sequential arm (Arm S) received 6 weekly R (375\u2003mg\/m<jats:sup>2<\/jats:sup>) treatments following six cycles of CHOP. Sixty\u2010nine patients were randomized but two patients were withdrawn before receiving the protocol treatment. Sixty\u2010five patients (94%) had follicular lymphoma, and 37 (55%) were at low risk, 23 (34%) at intermediate risk and seven (10%) at high risk according to the Follicular Lymphoma International Prognostic Index. We previously reported that the overall response rate (ORR) in Arm C and in Arm S was 94% and 97%, respectively. The median progression\u2010free survival (PFS)\/7\u2010year PFS rate in Arm C, Arm S and all 67 assessable patients was 2.4\u2003years\/23% (95% confidence interval [CI], 9\u201340%), 3.8\u2003years\/41% (95% CI, 23\u201357%) and 2.8\u2003years\/32% (95% CI, 20\u201345%), respectively. There was no significant difference between the two arms (<jats:italic>P<\/jats:italic>\u2003=\u20030.107). The overall survival (OS) of the 67 patients was 95% at 7\u2003years. In conclusion, R\u2010CHOP is a highly effective initial treatment for untreated indolent B\u2010NHL in terms of ORR and OS; however, its long\u2010term PFS is not good enough either in concurrent or sequential combination, warranting further investigations on post\u2010remission therapy. (<jats:italic>Cancer Sci<\/jats:italic> 2010; 101: 2579\u20132585)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2010.01703.x","type":"journal-article","created":{"date-parts":[[2010,8,3]],"date-time":"2010-08-03T07:18:56Z","timestamp":1280819936000},"page":"2579-2585","source":"Crossref","is-referenced-by-count":13,"title":["Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B\u2010cell non\u2010Hodgkin lymphoma: 7\u2010year follow\u2010up results"],"prefix":"10.1111","volume":"101","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiko","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"all collaborators of the IDEC\u2010C2B8 Study Group in Japan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1398"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708875"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-041871"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.027"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.052"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.404"},{"issue":"5","key":"e_1_2_7_23_2","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin\u2019s lymphomas","volume":"5","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00173.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_7_29_2","first-page":"843a","article-title":"A phase II trial of CHOP followed by rituximab chimeric monoclonal anti\u2010CD20 antibody for treatment of newly diagnosed follicular non\u2010Hodgkin\u2019s lymphoma: SWOG 9800","volume":"98","author":"Maloney DG","year":"2001","journal-title":"Blood"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jjco.a039642"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_35_2","doi-asserted-by":"crossref","first-page":"901a","DOI":"10.1182\/blood.V112.11.2599.2599","article-title":"Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow\u2010up of 58 months","volume":"112","author":"Buske C","year":"2008","journal-title":"Blood"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.8198"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2010.01703.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2010.01703.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:55:04Z","timestamp":1697439304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2010.01703.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1349-7006.2010.01703.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01703.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"type":"print","value":"1347-9032"},{"type":"electronic","value":"1349-7006"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}